ライフサイエンスコーパス: PAV

1 PAV increased by 0.3% (p < 0.001), and 19.9% of subjects

2 PAV-TAS2R38 mRNA expression was measured in 18 of 22 het

3 V delivered with the Puritan-Bennett 7200ae, PAV is associated with more rapid improvements in some p

4 of the children of the AVI/AVI, PAV/AVI, and PAV/PAV genotypes differed from each other, and that the

5 eline) and was attenuated with hyperoxia and PAV (-18 +/- 1 and -17 +/- 2% baseline, P < 0.01, respec

6 iking scores of the children of the AVI/AVI, PAV/AVI, and PAV/PAV genotypes differed from each other,

7 ctors associated with MACE included baseline PAV (p < 0.0001), change in PAV (p = 0.002), smoking (p

8 Greater baseline PAVs were observed in patients who experienced myocardia

9 A stronger correlation was observed between PAV and glycated hemoglobin (r = 0.22, p = 0.0003) than

10 In human whole blood, PAV coating at high dose (100 microg/ml) induced elevate

11 3'TE in cis and capped mRNA lacking any BYDV-PAV sequence was inhibited specifically by added 3'TE RN

12 etitive hierarchy: the coinoculation of BYDV-PAV lowered CYDV-RPV infection rate, but the reverse was

13 species, barley yellow dwarf virus-PAV (BYDV-PAV) and cereal yellow dwarf virus-RPV (CYDV-RPV).

14 The BYDV-PAV 5'UTR was necessary for the 3'TE to function, except

15 e of the PAV barley yellow dwarf virus (BYDV-PAV) which stimulates translation from uncapped mRNA by

16 ibody, but no correlation with the anti-carp PAV monoclonal antibody.

17 Many of the genes affected by CNV/PAV are either maize specific (thus possible annotation

18 Over 70% of the CNV/PAV examples are identified in multiple genotypes, and t

19 yed a positive correlation with the anti-cod PAV polyclonal antibody, but no correlation with the ant

20 ent, the mean increase of distance-corrected PAV for near vision was +0.25+/-0.64 D (P < 0.001) for d

21 ntly influence liking of accessions, despite PAV/PAV 'supertasters' scoring higher for this attribute

22 The immuno-detected PAV contents of the test fish species were estimated by

23 Coating of high dose PAV with CHC significantly reduced these responses.

24 Low dose PAV (10 microg/ml) +/- CHC and unmodified alginate micro

25 least one genotype relative to B73 (DownCNV/PAV).

26 Many of these DownCNV/PAV are examples of genes present in B73, but missing fr

27 antibodies for the southern hemisphere fish PAV.

28 and this reduction was attenuated following PAV exercise (-20 +/- 5%; P < 0.05).

29 17.0% [95% CI, 10.4% to 23.6%]; P < .001 for PAV and 61.5% vs 48.9%; difference, 12.5% [95% CI, 5.9%

30 atorvastatin and 68.5% with rosuvastatin for PAV (P=0.07) and 64.7% and 71.3%, respectively, for TAV

31 TAS2R38 polymorphisms encode functional (PAV: proline, alanine, and valine at positions 49, 262,

32 Children of the genotype PAV/AVI were reported using more vegetables, but not ber

33 notype AVI/AVI, and 40% were of the genotype PAV/AVI.

34 In the rimonabant vs placebo groups, PAV (95% confidence interval [CI]) increased 0.25% (-0.0

35 o acid sequence) form do not; heterozygotes (PAV/AVI) show the widest range of bitter perception.

36 The continuous rate of change in PAV (1.1 +/- 0.4% vs. 0.8 +/- 0.4%, p = 0.34) and TAV (1

37 ncluded baseline PAV (p < 0.0001), change in PAV (p = 0.002), smoking (p = 0.0002) and hypertension (

38 parameters were prespecified: the change in PAV and the change in nominal atheroma volume in the 10-

39 The mean (SD) change in PAV for the entire vessel was -0.98% (3.15%), with a med

40 ge in atheroma burden (at least 5% change in PAV, 70% vs. 53%, p < 0.001).

41 h placebo, resulted in a greater decrease in PAV after 76 weeks of treatment.

42 seline characteristics showed an increase in PAV of 0.64% (95% CI, 0.23% to 1.05%) for glimepiride an

43 Each standard deviation increase in PAV was associated with a 1.20-fold (95% confidence inte

44 Each standard deviation increase in PAV was associated with a 1.32-fold (95% confidence inte

45 (21.1 +/- 3.7 months), greater increases in PAV, but not total atheroma volume, were observed in sub

46 tive or positive postoperative SA increased, PAV for intermediate and near vision increased.

47 Least squares mean PAV increased 0.73% (95% CI, 0.33% to 1.12%) with glimep

48 erative adaptive optics assessment, the mean PAV increase at near was significantly higher (P < 0.05)

49 With medical therapy, the rate of change of PAV (0.7 +/- 0.6% vs. 0.7 +/- 0.5%, p = 0.92) and TAV (-

50 mine individual differences in expression of PAV-TAS2R38 messenger RNA (mRNA) among heterozygotes, to

51 atted to assess relative immunoreactivity of PAV.

52 may occur with this more realistic model of PAV.

53 DL-C was associated with less progression of PAV (+0.30%, 95% confidence interval [CI]: -0.17% to 0.7

54 n was associated with greater progression of PAV (+0.43 +/- 0.07% vs. +0.02 +/- 0.11%; p = 0.002).

55 was not associated with less progression of PAV (+0.51%, 95% CI: 0.04% to 0.99% vs. +0.61%, 95% CI:

56 More rapid progression of PAV (0.6 +/- 0.4% vs. 0.05 +/- 0.3%, p = 0.0001) and TAV

57 participants who demonstrated regression of PAV (56.9% vs 48.9%; P = .08) and TAV (64.4% vs 57.5%; P

58 uvastatin, a similar degree of regression of PAV was observed in the two treatment groups.

59 "runaway" phenomenon with the normal use of PAV.

60 5 719 genes were affected by an SNP, CNV, or PAV across the panel, providing a firm foundation to ide

61 The primary IVUS efficacy parameter, PAV, did not differ between participants treated with al

62 The primary efficacy parameter, PAV, increased 0.05% with placebo and decreased 0.95% wi

63 ine the correlation between the parvalbumin (PAV) contents and their corresponding immunoreactivity (

64 sease progression for the primary end point (PAV) but showed a favorable effect on the secondary end

65 e modified using proprietary polyallylamine (PAV) and coupled with macromolecular heparin conjugates

66 pav encodes a kinesin-like protein, PAV-KLP, related to the mammalian MKLP-1.

67 or proportional assist ventilation protocol (PAV+, Puritan Bennett 840; Covidien, Boulder, CO).

68 rial tachycardia/atrial fibrillation and SAV/PAV to the loss increased.

69 d paced atrioventricular (AV) intervals (SAV/PAV) accounted for 34.5% of all ventricular sensing epis

70 Inappropriately programmed SAV/PAV intervals was the most common reason for episodes of

71 We provide evidence that PAV-TAS2R38 expression amount correlates with individual

72 We hypothesized that PAV for NPPV would support gas exchange and avoid intuba

73 We suggest that PAV-KLP is required both to establish the structure of t

74 The PAV-CHC strategy resulted in uniform and stable coatings

75 t time a statistical correlation between the PAV content and the immunoreactivity and allowed to rank

76 For the PAV trial, despite reducing the work of breathing to a g

77 stics, although pH was slightly lower in the PAV group (7.30 versus 7.35, p = 0.02).

78 d, and there were fewer complications in the PAV group.

79 ty-one and 23 patients were entered into the PAV and PSV groups, respectively, and had similar diagno

80 translated region (UTR) of the genome of the PAV barley yellow dwarf virus (BYDV-PAV) which stimulate

81 was a strong phylogenetic association of the PAV immunoreactivity.

82 We conclude that use of the PAV mode is feasible for noninvasive therapy of acute re

83 At low concentrations, people with the PAV ("taster" amino acid sequence) form of TAS2R38 perce

84 stics for patients not completing the trial, PAV increased 0.25% (-0.04% to 0.55%) vs 0.57% (0.29% to

85 , defined as the pseudo-accommodation value (PAV = [1/reading distance {m}] - minimum addition [D]).

86 -CNVs) and 14 430 presence/absence variants (PAVs), affecting a total of 9979 genes, including two up

87 iation (CNV) and presence-absence variation (PAV) can lead to variation in the genome content of indi

88 vantages of proportional assist ventilation (PAV) has been the automatic synchrony between the end of

89 Proportional assist ventilation (PAV) is a newer mode that delivers assisted ventilation

90 educed via a proportional assist ventilator (PAV).

91 TRL) using a proportional assist ventilator (PAV).

92 g sequences in the barley yellow dwarf virus PAV genome required for this programmed readthrough in v

93 stop codon of the barley yellow dwarf virus (PAV serotype) coat protein gene is read through at a low

94 two virus species, barley yellow dwarf virus-PAV (BYDV-PAV) and cereal yellow dwarf virus-RPV (CYDV-R

95 the viral pathogen Barley yellow dwarf virus-PAV.

96 plaque in terms of percent atheroma volume (PAV) (33.9 +/- 10.2% vs. 37.8 +/- 10.3%, p < 0.001) and

97 onstrated a greater percent atheroma volume (PAV) (36.0 +/- 7.6% vs. 29.0 +/- 8.5%; p < 0.001) and to

98 onstrated a greater percent atheroma volume (PAV) (40.2 +/- 0.9% vs. 37.5 +/- 0.8%, p < 0.0001) and t

99 ts had a greater percentage atheroma volume (PAV) (45% vs. 34%, p < 0.001), total atheroma volume (TA

100 less progression in percent atheroma volume (PAV) (p < 0.001) and total atheroma volume (TAV) (p < 0.

101 changes in coronary percent atheroma volume (PAV) and CaI were measured across matched coronary segme

102 eline and change in percent atheroma volume (PAV) and total atheroma volume with incident major adver

103 r was the change in percent atheroma volume (PAV) from baseline to study completion.

104 Change in percent atheroma volume (PAV) from baseline to study completion.

105 e nominal change in percent atheroma volume (PAV) from baseline to week 78, measured by serial intrav

106 efficacy end point, percent atheroma volume (PAV), decreased by 0.99% (95% confidence interval [CI],

107 of regression using percent atheroma volume (PAV), the most rigorous IVUS measure of disease progress

108 meter was change in percent atheroma volume (PAV); the secondary efficacy parameter was change in nor

109 no-statin therapy (n = 224) associated with PAV progression (+0.8 +/- 0.1% and +1.0 +/- 0.1%; p < 0.

110 cteristics, HIST (n = 1,545) associated with PAV regression from baseline (-0.6 +/- 0.1%; p < 0.001),

111 y be an inherent shortcoming associated with PAV.

112 We show that Polo kinase associates with PAV-KLP with which it shows an overlapping pattern of su

113 iciency were randomized to receive NPPV with PAV delivered using the Respironics Vision ventilator or